Max Healthcare shares tumble 20% in three weeks, hitting two-year low

Max Healthcare Institute saw its share price drop 7% in the past three trading days and about 20% over the previous three weeks, reaching a two-year low not seen since August 2024. The decline follows reports that the Government of India intends to broaden a 30% price-cap rule to include non-scheduled cancer drugs, a move aimed at curbing high mark-ups and improving affordability. While analysts expect the margin hit to be short-lived, they note lingering regulatory uncertainty and ongoing concerns about consumable mark-ups.

The company also contends with increased exposure to the Central Government Health Scheme, which implemented higher package rates for medical procedures on October 13, 2025, affecting several of its hospitals in Mohali, Dwarka, Vaishali, Bathinda, BLK, Shalimar Bagh and Dehradun. Competition from other large providers such as Fortis, Apollo and Medanta adds further pressure. Future performance will hinge on the firm's ability to boost profitability, expand capacity and diversify through asset-light ventures like Max Labs and Max Homes.